Want to see AARD full AI Analyst Report?
Top Page
Aardvark Therapeutics, Inc.
(NASDAQ:AARD)
Select Model
Select Model
Rating:49Neutral
Price Target:
$7.00
▲(10.76% Upside)
Action:Reiterated
Date:08/18/26
The score is held down primarily by weak financial performance (no revenue, widening losses, and significant cash burn implying ongoing reliance on external funding), partially offset by a low-debt balance sheet. Technicals are broadly neutral with some near-term support versus mid-term averages but still below the long-term trend, while valuation remains challenging due to negative earnings. Corporate events add a small positive for governance and leadership continuity, tempered by potential dilution/compensation impacts.
Positive Factors
Low Financial Leverage
Very low debt relative to equity limits solvency pressure and preserves financial flexibility. This gives Aardvark more room to fund clinical development and manage setbacks without substantial interest or principal obligations.
Negative Factors
No Revenue and Widening Losses
Aardvark has not yet demonstrated commercial revenue or operating leverage, while losses are expanding with development spending. Until a product or partnership generates income, earnings remain highly dependent on successful clinical and regulatory execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
Very low debt relative to equity limits solvency pressure and preserves financial flexibility. This gives Aardvark more room to fund clinical development and manage setbacks without substantial interest or principal obligations.
Read all positive factors
Aardvark Therapeutics, Inc. (AARD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$150.57M
Dividend YieldN/A
Average Volume (3M)382.31K
Price to Earnings (P/E)―
Beta (1Y)2.39
Revenue GrowthN/A
EPS Growth-89.45%
CountryUS
Employees28
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.21
Shares Outstanding21,884,846
10 Day Avg. Volume240,671
30 Day Avg. Volume382,312
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.69
Price to Sales (P/S)0.00
P/FCF Ratio-5.28
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.25Price Target Upside-16.93% Downside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)-3.25
Revenue Forecast (FY)N/A
Aardvark Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic p...
How the Company Makes Money
null...
Aardvark Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
64
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -69.86M | -57.55M | -22.65M | -6.56M | -10.76M |
| Net Income | -69.89M | -57.59M | -20.59M | -7.21M | -13.56M |
Balance Sheet | |||||
| Total Assets | 81.46M | 117.18M | 77.51M | 10.54M | 16.76M |
| Cash, Cash Equivalents and Short-Term Investments | 73.87M | 110.03M | 73.66M | 9.99M | 16.11M |
| Total Debt | 677.00K | 441.00K | 779.00K | 162.00K | 262.00K |
| Total Liabilities | 6.66M | 10.55M | 132.15M | 45.34M | 44.68M |
| Stockholders Equity | 74.80M | 106.63M | -54.64M | -34.80M | -27.92M |
Cash Flow | |||||
| Free Cash Flow | -69.41M | -54.27M | -18.20M | -5.82M | -10.54M |
| Operating Cash Flow | -69.41M | -54.17M | -18.09M | -5.82M | -10.54M |
| Investing Cash Flow | 116.55M | -49.67M | -12.00M | 0.00 | -1.00M |
| Financing Cash Flow | 711.00K | 89.25M | 81.99M | 0.00 | 225.00K |
Aardvark Therapeutics, Inc. Risk Analysis
Aardvark Therapeutics, Inc. disclosed 90 risk factors in its most recent earnings report. Aardvark Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
We may use certain artificial intelligence (AI) technologies, which present risks and challenges that could adversely impact our business. Q2, 2026
Aardvark Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | $150.57M | -2.14 | -71.54% | ― | ― | -89.45% | |
46 Neutral | $139.50M | -8.58 | -41.15% | ― | -100.00% | 64.23% | |
45 Neutral | $168.39M | -0.86 | -1032.19% | ― | 354.37% | -63.33% | |
44 Neutral | $42.19M | -0.14 | 77.63% | ― | 6.81% | 11.95% | |
44 Neutral | $185.51M | -1.65 | -39.64% | ― | ― | -6.70% | |
43 Neutral | $123.21M | -1.46 | 44.63% | ― | 3.03% | 57.71% |
* General Sector Average
AARD
Aardvark Therapeutics, Inc.
7.25
-2.28
-23.92%
KPTI
Karyopharm Therapeutics
1.92
-5.54
-74.26%
CUE
Cue Biopharma
26.76
1.56
6.19%
EQ
Equillium
2.18
0.23
11.79%
ADCT
ADC Therapeutics
1.04
-2.13
-67.19%
NKTX
Nkarta
2.71
0.50
22.62%
Aardvark Therapeutics, Inc. Corporate Events
Executive/Board ChangesShareholder Meetings
Aardvark Therapeutics Shareholders Approve Governance and Incentives
Positive
Aug 17, 2026
At its August 14, 2026 annual meeting, Aardvark Therapeutics, Inc. recorded a quorum with approximately 54.79% of outstanding shares represented, as stockholders voted on director elections, auditor ratification, and equity compensation matters. I...
Business Operations and StrategyExecutive/Board Changes
Aardvark Therapeutics Implements Executive Retention Bonus Agreements
Positive
Jun 12, 2026
On June 10, 2026, Aardvark Therapeutics, Inc. entered into a retention bonus agreement with its Chief Financial Officer and Chief Operating Officer, Nelson Sun, providing for a total cash retention bonus of $346,500, combining a guaranteed 2026 an...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.